Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Tóm tắt
Từ khóa
Tài liệu tham khảo
2019, European Network of Cancer Registries Factsheets
Kitahara, 2016, The changing incidence of thyroid cancer, Nat Rev Endocrinol, 12, 646, 10.1038/nrendo.2016.110
Dal Maso, 2017, Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5, Eur J Cancer, 77, 140, 10.1016/j.ejca.2017.02.023
Vaccarella, 2016, Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis, N Engl J Med, 375, 614, 10.1056/NEJMp1604412
Ahn, 2015, South Korea's thyroid-cancer “epidemic”–turning the tide, N Engl J Med, 373, 2389, 10.1056/NEJMc1507622
Bibbins-Domingo, 2017, Screening for thyroid cancer: US Preventive Services Task Force Recommendation Statement, JAMA, 317, 1882, 10.1001/jama.2017.4011
Pacini, 2006, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, Eur J Endocrinol, 154, 787, 10.1530/eje.1.02158
Haugen, 2016, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, Thyroid, 26, 1, 10.1089/thy.2015.0020
Mitchell, 2016, Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines, J Laryngol Otol, 130, S150, 10.1017/S0022215116000578
Pacini, 2018, Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies, J Endocrinol Invest, 41, 849, 10.1007/s40618-018-0884-2
Cibas, 2009, The Bethesda system for reporting thyroid cytopathology, Am J Clin Pathol, 132, 658, 10.1309/AJCPPHLWMI3JV4LA
Maletta, 2016, Cytological features of “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology, Hum Pathol, 54, 134, 10.1016/j.humpath.2016.03.014
Nikiforova, 2018, Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules, Cancer, 124, 1682, 10.1002/cncr.31245
Nikiforov, 2016, Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors, JAMA Oncol, 2, 1023, 10.1001/jamaoncol.2016.0386
Williams, 2000, Guest editorial: two proposals regarding the terminology of thyroid tumors, Int J Surg Pathol, 8, 181, 10.1177/106689690000800304
Lloyd, 2017
Asioli, 2010, Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases, Am J Surg Pathol, 34, 44, 10.1097/PAS.0b013e3181c46677
Volante, 2007, Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach, Am J Surg Pathol, 31, 1256, 10.1097/PAS.0b013e3180309e6a
2014, Integrated genomic characterization of papillary thyroid carcinoma, Cell, 159, 676, 10.1016/j.cell.2014.09.050
Ibrahimpasic, 2017, Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence, Clin Cancer Res, 23, 5970, 10.1158/1078-0432.CCR-17-1183
Landa, 2016, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers, J Clin Invest, 126, 1052, 10.1172/JCI85271
Pozdeyev, 2018, Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers, Clin Cancer Res, 24, 3059, 10.1158/1078-0432.CCR-18-0373
Brierley, 2016
Grani, 2018, Follicular thyroid cancer and Hurthle cell carcinoma: challenges in diagnosis, treatment, and clinical management, Lancet Diabetes Endocrinol, 6, 500, 10.1016/S2213-8587(17)30325-X
Moon, 2017, Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis, Thyroid, 27, 651, 10.1089/thy.2016.0350
Vuong, 2017, Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-a meta-analysis, Clin Endocrinol (Oxf), 87, 411, 10.1111/cen.13413
Castagna, 2011, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients, Eur J Endocrinol, 165, 441, 10.1530/EJE-11-0466
Momesso, 2016, Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine, J Clin Endocrinol Metab, 101, 2692, 10.1210/jc.2015-4290
Park, 2017, Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy, Thyroid, 27, 524, 10.1089/thy.2016.0477
Ito, 2018, Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials, Eur J Surg Oncol, 44, 307, 10.1016/j.ejso.2017.03.004
Miyauchi, 2018, Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance, Surgery, 163, 48, 10.1016/j.surg.2017.03.028
Adam, 2014, Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients, Ann Surg, 260, 601, 10.1097/SLA.0000000000000925
Bilimoria, 2007, Extent of surgery affects survival for papillary thyroid cancer, Ann Surg, 246, 375, 10.1097/SLA.0b013e31814697d9
Randolph, 2011, The surgical management of goiter: Part II. Surgical treatment and results, Laryngoscope, 121, 68, 10.1002/lary.21091
Hauch, 2014, Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons, Ann Surg Oncol, 21, 3844, 10.1245/s10434-014-3846-8
Zhao, 2017, Evaluating the effectiveness of prophylactic central neck dissection with total thyroidectomy for cN0 papillary thyroid carcinoma: an updated meta-analysis, Eur J Surg Oncol, 43, 1989, 10.1016/j.ejso.2017.07.008
Hughes, 2018, Prophylactic central compartment neck dissection in papillary thyroid cancer and effect on locoregional recurrence, Ann Surg Oncol, 25, 2526, 10.1245/s10434-018-6528-0
Chen, 2018, Prophylactic central neck dissection for papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes: a systematic review and meta-analysis, World J Surg, 42, 2846, 10.1007/s00268-018-4547-4
Barczynski, 2013, Prophylactic central neck dissection for papillary thyroid cancer, Br J Surg, 100, 410, 10.1002/bjs.8985
Pacini, 2006, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study, J Clin Endocrinol Metab, 91, 926, 10.1210/jc.2005-1651
Luster, 2008, Guidelines for radioiodine therapy of differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 35, 1941, 10.1007/s00259-008-0883-1
Lamartina, 2015, Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature, J Clin Endocrinol Metab, 100, 1748, 10.1210/jc.2014-3882
Durante, 2010, Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas, J Clin Endocrinol Metab, 95, 4882, 10.1210/jc.2010-0762
Verburg, 2016, Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 43, 1001, 10.1007/s00259-016-3327-3
Schlumberger, 2012, Strategies of radioiodine ablation in patients with low-risk thyroid cancer, N Engl J Med, 366, 1663, 10.1056/NEJMoa1108586
Mallick, 2012, Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer, N Engl J Med, 366, 1674, 10.1056/NEJMoa1109589
Schlumberger, 2018, Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial, Lancet Diabetes Endocrinol, 6, 618, 10.1016/S2213-8587(18)30113-X
Dehbi, 2019, Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial, Lancet Diabetes Endocrinol, 7, 44, 10.1016/S2213-8587(18)30306-1
Lamartina, 2018, Recent advances in managing differentiated thyroid cancer, F1000Res, 7, 86., 10.12688/f1000research.12811.1
Giovanella, 2014, Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper, Eur J Endocrinol, 171, R33, 10.1530/EJE-14-0148
Spencer, 2011, Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC), J Clin Endocrinol Metab, 96, 3615, 10.1210/jc.2011-1740
Crocetti, 2008, Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients, Thyroid, 18, 1049, 10.1089/thy.2008.0160
Brassard, 2011, Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients, J Clin Endocrinol Metab, 96, 1352, 10.1210/jc.2010-2708
Durante, 2012, Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?, J Clin Endocrinol Metab, 97, 2748, 10.1210/jc.2012-1123
Angell, 2014, In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation, Thyroid, 24, 1127, 10.1089/thy.2013.0691
Grani, 2014, Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy, J Clin Endocrinol Metab, 99, 1970, 10.1210/jc.2014-1098
Torlontano, 2004, Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases, J Clin Endocrinol Metab, 89, 3402, 10.1210/jc.2003-031521
Grani, 2018, Interobserver agreement of various thyroid imaging reporting and data systems, Endocr Connect, 7, 1, 10.1530/EC-17-0336
Lamartina, 2016, Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer, J Clin Endocrinol Metab, 101, 3036, 10.1210/jc.2016-1440
Leboulleux, 2007, Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer, J Clin Endocrinol Metab, 92, 3590, 10.1210/jc.2007-0444
Leenhardt, 2013, 2013 European Thyroid Association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer, Eur Thyroid J, 2, 147, 10.1159/000354537
Lamartina, 2016, ENDOCRINE TUMOURS: imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach, Eur J Endocrinol, 175, R185, 10.1530/EJE-16-0088
Leboulleux, 2007, The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers, Nat Rev Endocrinol, 3, 112, 10.1038/ncpendmet0402
Robbins, 2006, Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning, J Clin Endocrinol Metab, 91, 498, 10.1210/jc.2005-1534
Nascimento, 2015, Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer, Thyroid, 25, 437, 10.1089/thy.2014.0320
Deandreis, 2011, Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?, Endocr Relat Cancer, 18, 159, 10.1677/ERC-10-0233
Robbins, 2008, The value of positron emission tomography (PET) in the management of patients with thyroid cancer, Best Pract Res Clin Endocrinol Metab, 22, 1047, 10.1016/j.beem.2008.10.001
Terroir, 2017, The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 44, 638, 10.1007/s00259-016-3551-x
Grani, 2019, Thyroid cancer patients with no evidence of disease: the need for repeat neck ultrasound, J Clin Endocrinol Metab, 104, 4981, 10.1210/jc.2019-00962
Miyauchi, 2011, Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy, Thyroid, 21, 707, 10.1089/thy.2010.0355
Durante, 2006, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J Clin Endocrinol Metab, 91, 2892, 10.1210/jc.2005-2838
Osorio, 2017, Systematic review of site distribution of bone metastases in differentiated thyroid cancer, Head Neck, 39, 812, 10.1002/hed.24655
Ruegemer, 1988, Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables, J Clin Endocrinol Metab, 67, 501, 10.1210/jcem-67-3-501
Schlumberger, 2014, Definition and management of radioactive iodine-refractory differentiated thyroid cancer, Lancet Diabetes Endocrinol, 2, 356, 10.1016/S2213-8587(13)70215-8
McGriff, 2002, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer, Ann Med, 34, 554, 10.1080/078538902321117760
Sugitani, 2010, Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial, J Clin Endocrinol Metab, 95, 4576, 10.1210/jc.2010-0161
Carhill, 2015, Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012, J Clin Endocrinol Metab, 100, 3270, 10.1210/JC.2015-1346
Deandreis, 2017, Comparison of empiric versus whole-body/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer, J Nucl Med, 58, 717, 10.2967/jnumed.116.179606
Falchook, 2015, BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer, Thyroid, 25, 71, 10.1089/thy.2014.0123
Dunn, 2019, Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers, J Clin Endocrinol Metab, 104, 1417, 10.1210/jc.2018-01478
Ho, 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer, N Engl J Med, 368, 623, 10.1056/NEJMoa1209288
Mazziotti, 2018, Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience, Endocrine, 59, 90, 10.1007/s12020-017-1455-6
Choksi, 2017, Skeletal complications and mortality in thyroid cancer: a population-based study, J Clin Endocrinol Metab, 102, 1254, 10.1210/jc.2016-3906
Wexler, 2011, Approach to the thyroid cancer patient with bone metastases, J Clin Endocrinol Metab, 96, 2296, 10.1210/jc.2010-1996
Hamadeh, 2015, Drug induced osteonecrosis of the jaw, Cancer Treat Rev, 41, 455, 10.1016/j.ctrv.2015.04.007
Drost, 2017, Efficacy of postoperative radiation treatment for bone metastases in the extremities, Radiother Oncol, 124, 45, 10.1016/j.radonc.2017.05.010
Deschamps, 2014, Percutaneous ablation of bone tumors, Diagn Interv Imaging, 95, 659, 10.1016/j.diii.2014.04.004
George, 2015, Interventions for the treatment of metastatic extradural spinal cord compression in adults, Cochrane Database Syst Rev, CD006716
Deschamps, 2016, Percutaneous osteosynthesis in the pelvis in cancer patients, Eur Radiol, 26, 1631, 10.1007/s00330-015-3971-1
de Baere, 2015, Interventional oncology for liver and lung metastases from colorectal cancer: the current state of the art, Diagn Interv Imaging, 96, 647, 10.1016/j.diii.2015.04.004
Venkatanarasimha, 2017, Radioembolisation of hepatocellular carcinoma: a primer, Clin Radiol, 72, 1002, 10.1016/j.crad.2017.07.021
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026
Sabra, 2017, Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma, Cancer, 123, 2955, 10.1002/cncr.30690
Brose, 2014, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 384, 319, 10.1016/S0140-6736(14)60421-9
Schlumberger, 2015, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer, N Engl J Med, 372, 621, 10.1056/NEJMoa1406470
Robinson, 2016, Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer, J Clin Endocrinol Metab, 101, 4103, 10.1210/jc.2015-3989
Brose, 2017, Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial, J Clin Oncol, 35, 2692, 10.1200/JCO.2016.71.6472
Berdelou, 2018, Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice, Thyroid, 28, 72, 10.1089/thy.2017.0205
Balmelli, 2018, Lenvatinib in advanced radioiodine-refractory thyroid cancer—a retrospective analysis of the Swiss Lenvatinib Named Patient Program, J Cancer, 9, 250, 10.7150/jca.22318
Cohen, 2008, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study, J Clin Oncol, 26, 4708, 10.1200/JCO.2007.15.9566
Locati, 2014, Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments, Cancer, 120, 2694, 10.1002/cncr.28766
Cabanillas, 2017, Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial, J Clin Oncol, 35, 3315, 10.1200/JCO.2017.73.0226
Brose, 2018, A phase 2 trial of cabozantinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma in the first-line setting, Int J Radiat Oncol Biol Phys, 100, 1311, 10.1016/j.ijrobp.2017.12.028
Sherman, 2008, Motesanib diphosphate in progressive differentiated thyroid cancer, N Engl J Med, 359, 31, 10.1056/NEJMoa075853
Schlumberger, 2018, A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209, J Clin Oncol, 36, 6021., 10.1200/JCO.2018.36.15_suppl.6021
Bible, 2010, Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study, Lancet Oncol, 11, 962, 10.1016/S1470-2045(10)70203-5
Carr, 2010, Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation, Clin Cancer Res, 16, 5260, 10.1158/1078-0432.CCR-10-0994
Leboulleux, 2012, Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial, Lancet Oncol, 13, 897, 10.1016/S1470-2045(12)70335-2
Brose, 2016, Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 1272, 10.1016/S1470-2045(16)30166-8
Drilon, 2018, Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children, N Engl J Med, 378, 731, 10.1056/NEJMoa1714448
French, 2017, Leveraging the immune system to treat advanced thyroid cancers, Lancet Diabetes Endocrinol, 5, 469, 10.1016/S2213-8587(16)30277-7
Haddad, 2017, Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes, Endocrine, 56, 121, 10.1007/s12020-017-1233-5
Subbiah, 2018, Selective RET kinase inhibition for patients with RET-altered cancers, Ann Oncol, 29, 1869, 10.1093/annonc/mdy137
Capdevila, 2018, Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer, Cancer Treat Rev, 69, 164, 10.1016/j.ctrv.2018.06.019
Tahara, 2019, Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer, Eur J Cancer, 106, 61, 10.1016/j.ejca.2018.10.002
Oktay, 2018, Fertility preservation in patients with cancer: ASCO clinical practice guideline update, J Clin Oncol, 36, 1994, 10.1200/JCO.2018.78.1914
Nagaiah, 2011, Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment, J Oncol, 2011, 1, 10.1155/2011/542358
Bogsrud, 2008, 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma, Thyroid, 18, 713, 10.1089/thy.2007.0350
Sugitani, 2018, Management of anaplastic thyroid carcinoma: the fruits from the ATC research consortium of Japan, J Nippon Med Sch, 85, 18, 10.1272/jnms.2018_85-3
Baek, 2017, Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012, Head Neck, 39, 133, 10.1002/hed.24559
Ito, 2012, Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors, Head Neck, 34, 230, 10.1002/hed.21721
Kwon, 2016, The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and meta-analysis, Eur J Cancer, 59, 34, 10.1016/j.ejca.2016.02.015
Bhatia, 2010, Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy, Head Neck, 32, 829, 10.1002/hed.21257
Sherman, 2011, Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review, Radiother Oncol, 101, 425, 10.1016/j.radonc.2011.09.004
Mohebati, 2014, Anaplastic thyroid carcinoma: a 25-year single-institution experience, Ann Surg Oncol, 21, 1665, 10.1245/s10434-014-3545-5
Pezzi, 2017, Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base, Cancer, 123, 1653, 10.1002/cncr.30493
De Crevoisier, 2004, Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy, Int J Radiat Oncol Biol Phys, 60, 1137, 10.1016/j.ijrobp.2004.05.032
Wang, 2006, Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens, Cancer, 107, 1786, 10.1002/cncr.22203
Dandekar, 2009, Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis, Int J Radiat Oncol Biol Phys, 74, 518, 10.1016/j.ijrobp.2008.08.016
Foote, 2011, Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy, Thyroid, 21, 25, 10.1089/thy.2010.0220
Smallridge, 2012, American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer, Thyroid, 22, 1104, 10.1089/thy.2012.0302
Shimaoka, 1985, A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma, Cancer, 56, 2155, 10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E
Ain, 2000, Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group, Thyroid, 10, 587, 10.1089/thy.2000.10.587
Sosa, 2014, Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma, Thyroid, 24, 232, 10.1089/thy.2013.0078
Tahara, 2017, Lenvatinib for anaplastic thyroid cancer, Front Oncol, 7, 25., 10.3389/fonc.2017.00025
Cabanillas, 2018, Recent advances and emerging therapies in anaplastic thyroid carcinoma [version 1; referees: 3 approved], F1000Res, 7, 87, 10.12688/f1000research.13124.1
Subbiah, 2018, Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer, J Clin Oncol, 36, 7, 10.1200/JCO.2017.73.6785
Wirth, 2018, Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer, J Clin Oncol, 36, 6024, 10.1200/JCO.2018.36.15_suppl.6024
Agrawal, 2013, Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS, J Clin Endocrinol Metab, 98, E364, 10.1210/jc.2012-2703
Elisei, 2013, 2012 European Thyroid Association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer, Eur Thyroid J, 1, 216, 10.1159/000346174
Wells, 2015, Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma, Thyroid, 25, 567, 10.1089/thy.2014.0335
Romei, 2016, New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double, J Med Genet, 53, 729, 10.1136/jmedgenet-2016-103833
Costante, 2007, Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules, J Clin Endocrinol Metab, 92, 450, 10.1210/jc.2006-1590
Costante, 2009, Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls, Nat Rev Endocrinol, 5, 35, 10.1038/ncpendmet1023
Machens, 2010, Biomarker-based risk stratification for previously untreated medullary thyroid cancer, J Clin Endocrinol Metab, 95, 2655, 10.1210/jc.2009-2368
Barbet, 2005, Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma, J Clin Endocrinol Metab, 90, 6077, 10.1210/jc.2005-0044
Laure Giraudet, 2008, Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times, Eur J Endocrinol, 158, 239, 10.1530/EJE-07-0667
Meijer, 2010, Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis, Clin Endocrinol (Oxf), 72, 534, 10.1111/j.1365-2265.2009.03666.x
Hadoux, 2016, Management of advanced medullary thyroid cancer, Lancet Diabetes Endocrinol, 4, 64, 10.1016/S2213-8587(15)00337-X
Moley, 1999, Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection, Ann Surg, 229, 880, 10.1097/00000658-199906000-00016
Calcitonin A. Carcinoembryonic Antigen Doubling Time Calculator; https://www.thyroid.org/professionals/calculators/thyroid-cancer-carcinoma/ (12 June 2019, date last accessed).
Treglia, 2012, PET imaging in recurrent medullary thyroid carcinoma, Int J Mol Imaging, 2012, 1
Romero-Lluch, 2017, Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff, Eur J Nucl Med Mol Imaging, 44, 2004, 10.1007/s00259-017-3759-4
Bodei, 2004, Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas, Cancer Biother Radiopharm, 19, 65, 10.1089/108497804773391694
Hadoux, 2017, Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer, Best Pract Res Clin Endocrinol Metab, 31, 335, 10.1016/j.beem.2017.04.009
Wells, 2012, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial, J Clin Oncol, 30, 134, 10.1200/JCO.2011.35.5040
Elisei, 2013, Cabozantinib in progressive medullary thyroid cancer, J Clin Oncol, 31, 3639, 10.1200/JCO.2012.48.4659
Fox, 2013, Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma, Clin Cancer Res, 19, 4239, 10.1158/1078-0432.CCR-13-0071
Schlumberger, 2017, Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma, Ann Oncol, 28, 2813, 10.1093/annonc/mdx479
Trimboli, 2018, Efficacy of vandetanib in treating locally advanced or metastatic medullary thyroid carcinoma according to RECIST criteria: a systematic review and meta-analysis, Front Endocrinol (Lausanne), 9, 224., 10.3389/fendo.2018.00224
Bastholt, 2016, Effect of an outreach programme on vandetanib safety in medullary thyroid cancer, Eur Thyroid J, 5, 187, 10.1159/000448919
Iten, 2009, [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial, Cancer, 115, 2052, 10.1002/cncr.24272
Cherny, 2017, ESMO-Magnitude of Clinical Benefit Scale version 1.1, Ann Oncol, 28, 2340, 10.1093/annonc/mdx310